A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers

Podobne knjige/članki

• A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers
  od: Leong, Joel, et al.
  Izdano: (2014)
• Spiroindolone KAE609 for Falciparum and Vivax Malaria
  od: White, Nicholas J., et al.
  Izdano: (2014)
• Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor
  od: Goldgof, Gregory M., et al.
  Izdano: (2016)
• Cell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated Antimalarials
  od: Dennis, Adelaide S. M., et al.
  Izdano: (2018)
• Open-Label, Single-Dose, Parallel-Group Study in Healthy Volunteers To Determine the Drug-Drug Interaction Potential between KAE609 (Cipargamin) and Piperaquine
  od: Stein, Daniel S., et al.
  Izdano: (2015)